donepezil ARICEPT

Class: Acetylcholinesterase Inhibitor
FDA Indications: Alzheimer's Dementia
Off-Label Use: Motor Symptoms Of Parkinson's Disease, Mild Cognitive Impairment
Prescribing
Forms: 5, 10mg tablet; 5, 10mg ODT; 23mg sustained-release, film-coated tablet
Dose Range: 5-10 mg/day
Starting: 5 mg daily for 4, then can titrate to 10 mg daily. Morning dosing may minimize insomnia and vivid dreams.

NAMI drug fact sheet

Precautions
Contraindications: Known hypersensitivity to a specific drug or its derivatives is the only true contraindication. Cautious administration of cholinesterase inhibitors is advised in patients who have a previous history of allergy or adverse reactions to prior cholinesterase inhibitors, severe liver disease, preexisting bradycardia, peptic ulcer disease, current alcoholism, asthma, or chronic obstructive pulmonary disease.
Side Effects: diarrhea, nausea, insomnia, anorexia, fatigue, agitation, vomiting, vivid dreams, muscle cramps
Pharmacodynamics
1° MOA: Centrally acting, reversible, noncompetitive AChEI
2° MOA: High affinity σ1 agonist
Target: AChE, σ1
Pharmacokinetics
t½: 70° TMAX: 3-5°
Substrate of: 3A4; 2D6
Inhibits: ∅ ; Induces:
Active Metabolites: 6-O-desmethyl donepezil
DDIs
  • - AChEIs have the potential to interfere with the activity of anticholinergic medications
  • - A synergistic effect may be expected with concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists
  • - 3A4 inhibitors can ↑ levels; likewise, 3A4 inducers can ↓ levels
Misc
  • - a "nonclassical" cholinesterase inhibitor that binds to both AChE and butyrylcholinesterase
  • - displays linear pharmacokinetics
  • - has the best evidence for effectiveness in mild cognitive impairment of all cholinesterase inhibitors
  • - GI side effects can be minimized by gradual dose increases, administration with food, adequate hydration, and judicious use of an antiemetic
Special Populations

Category C—No reports describing the use of donepezil in human pregnancy have been located. Because of its indication, such reports should be rare. Moreover, the animal data suggest that the risk to the embryo and/ or fetus is low. Therefore, inadvertent exposure to donepezil during pregnancy should not be a reason for pregnancy termination.

No reports describing the use of donepezil during human lactation have been located. The molecular weight of the parent compound and its long t½ suggest that donepezil, and possible the active metabolites, will be excreted into breast milk. The extensive protein binding (about 96%), however, should limit this excretion. The effects of this exposure on a nursing infant are unknown.

No dosage adjustment necessary.


Only a minimal dose decrease required in hepatic impairment.

logo

Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated May 19 2018 15:53:20. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.